glp-1 market size 2024 Receptor Agonist Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Receptor Agonist Market Size

Most millennials grew up in the '90s and 2000s, when heroin-chic and visible collarbones were all the rage

This knowledge ensures that the dosing schedule, recommended dosage, and potential benefits align with your specific needs

Alamin A, Gupta V

Key highlights Tirzepatide is the first dual GLP-1/GIP receptor agonist that offers stronger appetite suppression, improved glycemic control, and provides significantly greater weight loss than single receptor agonists such as semaglutide, liraglutide, and dulaglutide

FDA also noted that submitted COA information did not include results addressing all relevant impurity, aggregate, bioburden, and bacterial-endotoxin attributes

While these side effects are normal, its important to know how to manage them and when to seek help